This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MedChi Applauds Maryland Senate For Expanding Patient Access To Innovative Drugs

ANNAPOLIS, Md., March 11, 2013 /PRNewswire/ -- MedChi, The Maryland State Medical Society, applauds passage of legislation in the Maryland State Senate to create a process that will make newly developed biosimilar medications accessible in a safe and transparent manner for state residents. The legislation still has to pass hurdles in the House and be signed by the Governor to become law.

"Biosimilar drugs are now being used in Europe and will soon be authorized for patient use in this country," explained MedChi CEO Gene Ransom. " Maryland is being proactive in establishing a process by which patients have access to these affordable drugs with provisions to protect their safety."

The committee action fulfills the state's responsibilities under the federal Affordable Care Act (ACA). The ACA empowers states to set the standards by which biosimilars -- reproductions of brand-name biologic medications -- can be substituted for the innovator product. It is expected that biosimilars will be reaching pharmacies as early as 2014.

The State Senate measure, introduced by Sen. Joan Carter Conway, states that biosimilars can only be substituted if the Food and Drug Administration has certified the drugs as interchangeable with the original, brand-name biologic. This standard is made necessary by the fact that, unlike generic versions of conventional drugs, biologics are made from living cells and it is impossible to create exact copies. Even slight variations between the biologic and the biosimilar can make a difference in clinical outcomes.

Ransom explained, "Biologics are changing the lives of patients with serious chronic illnesses. Biosimilars will make this improved health financially accessible for more Marylanders, but because of the unique nature of these medications, patient safety must be assured. This committee action provides both accessibility and critical safeguards. This is common-sense, patient-centric legislation."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs